Sionna Therapeutics Inc SION
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-02-07 |
| Shares Out. | 45,150,000 |
| Website | sionnatx.com/ ↗ |
| Phone | 16178192020 |
| Employees | 59 |
| Net Income | -$26.8M |
| Free Cash Flow | -$72.1M |
| Total Assets | $305.0M |
| Total Liabilities | $16.8M |
| Equity | $288.2M |
About Sionna Therapeutics Inc
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Sionna Therapeutics Inc is a publicly traded company under the ticker symbol SION on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)